Company Filing History:
Years Active: 2011
Title: Vikram Krishna Ramanathan: Innovator of Cholesterol-Lowering Compounds
Introduction
Vikram Krishna Ramanathan is an accomplished inventor based in Haryana, India, recognized for his contributions to the pharmaceutical field. He has been instrumental in the development of innovative compounds that aim to combat cholesterol-related diseases.
Latest Patents
Ramathanan holds one significant patent titled "Substituted pyrrole derivatives and their use as HMG-CO inhibitors." This invention pertains to substituted pyrrole derivatives that serve as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. The compounds disclosed in this patent exhibit potential as cholesterol-lowering agents and provide avenues for the treatment of cholesterol-related ailments. Additionally, the patent outlines the processes for the preparation of these compounds, their pharmaceutical compositions, and methods for treating conditions associated with elevated cholesterol levels.
Career Highlights
Vikram currently works at Ranbaxy Laboratories, Inc., a notable player in the pharmaceutical industry. His role involves researching and developing new medications that address crucial health issues. With his expertise in chemistry and pharmaceuticals, he has made significant advancements in drug formulation and development.
Collaborations
Throughout his career, Vikram has collaborated with esteemed colleagues such as Mohammad Salman and Jitendra Anant Sattigeri. These partnerships contribute to a robust environment for innovation, allowing for the exchange of ideas and fostering breakthroughs in pharmaceutical research and development.
Conclusion
Vikram Krishna Ramanathan exemplifies the spirit of innovation in the pharmaceutical industry. His dedication to developing effective treatments for cholesterol-related diseases underscores the vital role of inventors like him in improving global health. Through his pioneering work, he continues to influence the landscape of medical research and pharmaceutical advancements.